Catecholaminergic polymorphic ventricular tachycardia 4
diseaseOn this page
Also known as CALM1 catecholaminergic polymorphic ventricular tachycardiacatecholaminergic polymorphic ventricular tachycardia caused by mutation in CALM1catecholaminergic polymorphic ventricular tachycardia type 4CPVT4ventricular tachycardia, catecholaminergic polymorphic, 4ventricular tachycardia, catecholaminergic polymorphic, type 4
Summary
Catecholaminergic polymorphic ventricular tachycardia 4 (MONDO:0013966) is a disease caused by CALM1 (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: CALM1 (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 128
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | catecholaminergic polymorphic ventricular tachycardia 4 |
| Mondo ID | MONDO:0013966 |
| OMIM | 614916 |
| DOID | DOID:0060678 |
| UMLS | C3554047 |
| MedGen | 766961 |
| GARD | 0015880 |
| Is cancer (heuristic) | no |
Also known as: CALM1 catecholaminergic polymorphic ventricular tachycardia · catecholaminergic polymorphic ventricular tachycardia 4 · catecholaminergic polymorphic ventricular tachycardia caused by mutation in CALM1 · catecholaminergic polymorphic ventricular tachycardia type 4 · CPVT4 · ventricular tachycardia, catecholaminergic polymorphic, 4 · ventricular tachycardia, catecholaminergic polymorphic, type 4
Data availability: 128 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart conduction disease › catecholaminergic polymorphic ventricular tachycardia › catecholaminergic polymorphic ventricular tachycardia 4
Related subtypes (6): catecholaminergic polymorphic ventricular tachycardia 1, catecholaminergic polymorphic ventricular tachycardia 2, catecholaminergic polymorphic ventricular tachycardia 3, catecholaminergic polymorphic ventricular tachycardia 5, long QT syndrome 16, ventricular tachycardia, catecholaminergic polymorphic 6
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
128 retrieved; paginated sample, class counts are floors:
83 likely benign, 21 uncertain significance, 8 pathogenic, 6 benign, 5 benign/likely benign, 2 conflicting classifications of pathogenicity, 2 likely pathogenic, 1 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1362982 | NM_006888.6(CALM1):c.395A>G (p.Asp132Gly) | CALM1 | Pathogenic | criteria provided, single submitter |
| 2100843 | NM_006888.6(CALM1):c.286G>T (p.Asp96Tyr) | CALM1 | Pathogenic | criteria provided, single submitter |
| 39758 | NM_006888.6(CALM1):c.293A>G (p.Asn98Ser) | CALM1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 426161 | NM_006888.6(CALM1):c.424T>C (p.Phe142Leu) | CALM1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 4785412 | NM_006888.6(CALM1):c.270C>G (p.Phe90Leu) | CALM1 | Pathogenic | criteria provided, single submitter |
| 4787824 | NM_006888.6(CALM1):c.389A>T (p.Asp130Val) | CALM1 | Pathogenic | criteria provided, single submitter |
| 639902 | NM_006888.6(CALM1):c.394G>A (p.Asp132Asn) | CALM1 | Pathogenic | criteria provided, single submitter |
| 948239 | NM_006888.6(CALM1):c.395A>T (p.Asp132Val) | CALM1 | Pathogenic | criteria provided, single submitter |
| 961658 | NM_006888.6(CALM1):c.426C>A (p.Phe142Leu) | CALM1 | Pathogenic | criteria provided, single submitter |
| 39757 | NM_006888.6(CALM1):c.161A>T (p.Asn54Ile) | CALM1 | Likely pathogenic | criteria provided, single submitter |
| 542137 | NM_006888.6(CALM1):c.398G>A (p.Gly133Glu) | CALM1 | Likely pathogenic | criteria provided, single submitter |
| 1086423 | NM_006888.6(CALM1):c.4-9T>A | CALM1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3826954 | NM_006888.6(CALM1):c.4-4A>G | CALM1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1062650 | NC_000014.8:g.(?90870713)(90871071_?)dup | CALM1 | Uncertain significance | criteria provided, single submitter |
| 1424459 | NM_006888.6(CALM1):c.328A>C (p.Met110Leu) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 1718023 | NM_006888.6(CALM1):c.358G>A (p.Glu120Lys) | CALM1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1740325 | NM_006888.6(CALM1):c.4-3T>C | CALM1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2061992 | NM_006888.6(CALM1):c.70G>A (p.Gly24Ser) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 2132986 | NM_006888.6(CALM1):c.402C>G (p.Asp134Glu) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 2425651 | NC_000014.8:g.(?90863575)(90871061_?)dup | CALM1 | Uncertain significance | criteria provided, single submitter |
| 2953702 | NM_006888.6(CALM1):c.398G>C (p.Gly133Ala) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3244035 | NC_000014.8:g.(?90863575)(90871061_?)del | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3748203 | NM_006888.6(CALM1):c.154A>G (p.Met52Val) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3756961 | NM_006888.6(CALM1):c.35-12_35-11delinsCC | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3759214 | NM_006888.6(CALM1):c.199C>T (p.Pro67Ser) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3759522 | NM_006888.6(CALM1):c.35-44_77dup | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3759525 | NM_006888.6(CALM1):c.293A>T (p.Asn98Ile) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 3902818 | NM_006888.6(CALM1):c.133A>G (p.Thr45Ala) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 475380 | NM_006888.6(CALM1):c.157A>G (p.Ile53Val) | CALM1 | Uncertain significance | criteria provided, single submitter |
| 4785968 | NM_006888.6(CALM1):c.178+4A>C | CALM1 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 7 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| CALM1 | Strong | Autosomal dominant | catecholaminergic polymorphic ventricular tachycardia 4 | 7 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| CALM1 | Orphanet:101016 | Romano-Ward syndrome |
| CALM1 | Orphanet:3286 | Catecholaminergic polymorphic ventricular tachycardia |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| CALM1 | HGNC:1442 | ENSG00000198668 | P0DP23 | Calmodulin-1 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| CALM1 | Calmodulin-1 | Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| CALM1 | Other/Unknown | no | EF_hand_dom, EF-hand-dom_pair, EF_Hand_1_Ca_BS |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| lateral nuclear group of thalamus | 1 |
| medial globus pallidus | 1 |
| parietal lobe | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| CALM1 | 295 | ubiquitous | marker | lateral nuclear group of thalamus, medial globus pallidus, parietal lobe |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| CALM1 | 25 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| CALM1 | P0DP23 | 337 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 144. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Ionotropic activity of kainate receptors | 1 | 5710.0× | 0.006 | CALM1 |
| Activation of kainate receptors upon glutamate binding | 1 | 5710.0× | 0.006 | CALM1 |
| Cam-PDE 1 activation | 1 | 2855.0× | 0.006 | CALM1 |
| Loss of phosphorylation of MECP2 at T308 | 1 | 2855.0× | 0.006 | CALM1 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 1 | 2284.0× | 0.006 | CALM1 |
| Metabolism of cofactors | 1 | 1903.3× | 0.006 | CALM1 |
| Glycogen metabolism | 1 | 1903.3× | 0.006 | CALM1 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | 1 | 1427.5× | 0.006 | CALM1 |
| Loss of function of MECP2 in Rett syndrome | 1 | 1427.5× | 0.006 | CALM1 |
| Pervasive developmental disorders | 1 | 1427.5× | 0.006 | CALM1 |
| Activation of RAC1 downstream of NMDARs | 1 | 1427.5× | 0.006 | CALM1 |
| Disorders of Developmental Biology | 1 | 1427.5× | 0.006 | CALM1 |
| Disorders of Nervous System Development | 1 | 1427.5× | 0.006 | CALM1 |
| Calcineurin activates NFAT | 1 | 1268.9× | 0.006 | CALM1 |
| The phototransduction cascade | 1 | 1268.9× | 0.006 | CALM1 |
| CASP4 inflammasome assembly | 1 | 1268.9× | 0.006 | CALM1 |
| CaMK IV-mediated phosphorylation of CREB | 1 | 1142.0× | 0.006 | CALM1 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 1 | 1142.0× | 0.006 | CALM1 |
| Activation of Ca-permeable Kainate Receptor | 1 | 1142.0× | 0.006 | CALM1 |
| Sodium/Calcium exchangers | 1 | 1038.2× | 0.006 | CALM1 |
| CLEC7A (Dectin-1) induces NFAT activation | 1 | 1038.2× | 0.006 | CALM1 |
| Reduction of cytosolic Ca++ levels | 1 | 951.7× | 0.006 | CALM1 |
| Uptake and function of anthrax toxins | 1 | 951.7× | 0.006 | CALM1 |
| eNOS activation | 1 | 878.5× | 0.006 | CALM1 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 1 | 878.5× | 0.006 | CALM1 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 1 | 878.5× | 0.006 | CALM1 |
| Downstream signaling events of B Cell Receptor (BCR) | 1 | 815.7× | 0.006 | CALM1 |
| Uptake and actions of bacterial toxins | 1 | 815.7× | 0.006 | CALM1 |
| Enterobacterial factors antagonize host defense | 1 | 815.7× | 0.006 | CALM1 |
| Glycogen breakdown (glycogenolysis) | 1 | 761.3× | 0.006 | CALM1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of ryanodine-sensitive calcium-release channel activity | 1 | 8426.0× | 0.001 | CALM1 |
| negative regulation of high voltage-gated calcium channel activity | 1 | 8426.0× | 0.001 | CALM1 |
| regulation of ryanodine-sensitive calcium-release channel activity | 1 | 5617.3× | 0.001 | CALM1 |
| organelle localization by membrane tethering | 1 | 5617.3× | 0.001 | CALM1 |
| negative regulation of calcium ion export across plasma membrane | 1 | 4213.0× | 0.001 | CALM1 |
| presynaptic endocytosis | 1 | 3370.4× | 0.001 | CALM1 |
| regulation of cardiac muscle cell action potential | 1 | 2808.7× | 0.001 | CALM1 |
| autophagosome membrane docking | 1 | 2407.4× | 0.001 | CALM1 |
| obsolete mitochondrion-endoplasmic reticulum membrane tethering | 1 | 2106.5× | 0.001 | CALM1 |
| regulation of cell communication by electrical coupling involved in cardiac conduction | 1 | 1872.4× | 0.001 | CALM1 |
| calcineurin-mediated signaling | 1 | 1532.0× | 0.002 | CALM1 |
| detection of calcium ion | 1 | 1123.5× | 0.002 | CALM1 |
| regulation of calcium-mediated signaling | 1 | 1123.5× | 0.002 | CALM1 |
| regulation of cardiac muscle contraction | 1 | 887.0× | 0.002 | CALM1 |
| regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 674.1× | 0.002 | CALM1 |
| regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 | 674.1× | 0.002 | CALM1 |
| cellular response to interferon-beta | 1 | 526.6× | 0.003 | CALM1 |
| regulation of heart rate | 1 | 468.1× | 0.003 | CALM1 |
| positive regulation of receptor signaling pathway via JAK-STAT | 1 | 432.1× | 0.003 | CALM1 |
| regulation of cytokinesis | 1 | 421.3× | 0.003 | CALM1 |
| substantia nigra development | 1 | 366.4× | 0.003 | CALM1 |
| response to calcium ion | 1 | 318.0× | 0.004 | CALM1 |
| G2/M transition of mitotic cell cycle | 1 | 312.1× | 0.004 | CALM1 |
| long-term synaptic potentiation | 1 | 280.9× | 0.004 | CALM1 |
| cellular response to type II interferon | 1 | 208.1× | 0.005 | CALM1 |
| G protein-coupled receptor signaling pathway | 1 | 36.2× | 0.028 | CALM1 |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| CALM1 | CLOZAPINE |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| CALM1 | 6 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| CLOZAPINE | 4 | CALM1 |
| TRIFLUOPERAZINE | 4 | CALM1 |
| PROMETHAZINE | 4 | CALM1 |
| CHLORPROMAZINE | 4 | CALM1 |
| HESPERIDIN | 3 | CALM1 |
| QUERCETIN | 3 | CALM1 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| CALM1 | 23 | Binding:23 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
6 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| CLOZAPINE | 4 | CALM1 |
| TRIFLUOPERAZINE | 4 | CALM1 |
| PROMETHAZINE | 4 | CALM1 |
| CHLORPROMAZINE | 4 | CALM1 |
| HESPERIDIN | 3 | CALM1 |
| QUERCETIN | 3 | CALM1 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | CALM1 |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: CALM1